• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Campath (alemtuzumab) Injection for intravenous use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- May 2009

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.

 

Summary View

 

WARNINGS AND PRECAUTIONS

Immunosuppression/Infections

  • The following sentence was rewritten: "Administer only irradiated blood products to avoid transfusion associated Graft versus Host Disease (TAGVHD), unless emergent circumstances dictate immediate transfusion."

ADVERSE REACTIONS

Postmarketing Experience

  • Cardiovascular: congestive heart failure...
  • Immune disorders: ...fatal transfusion associated Graft versus Host Disease
  • Infections: ...including EBV-associated lymphoproliferative disorder...re-activation of latent viruses.